Contains 0.3mg/ml of bimaprost as the main ingredient
Glaucoma treatment eye drops
It works to reduce intraocular pressure
Ocular hypertension treatmentEyelash growth
Hair thickening effectDomestic release
Glas Vista and
Same ingredients
-
-
Lumigan Ophthalmic Solution
Lumigan Solution
Manufacturer: Allergan / Volume: 3ml
Product Description
The bimaprost contained in Lumigan Solution works to lower intraocular pressure and is used to treat glaucoma and ocular hypertension.
How to use
When used as a treatment for glaucoma
Apply one drop to your eye once a day.When used to grow and thicken eyelashes
Apply to the base of your eyelashes once a day before going to bed.Ingredients
Bimatoprost 0.3mg/ml(0.03%)
Benzalkonium Chloride 0.05mg/mlUsage notes
Use within 30 days after opening.
Lumigan Solution is an eye drop medicine for treating glaucoma, but if you are using it to promote eyelash growth, never drop it into your eyes and be careful not to get the liquid in your eyes.
Also, be careful not to get the liquid on your skin.
After applying the liquid to the base of your eyelashes, wipe off any excess liquid on your skin.
Be sure to consult your doctor before using this product.
Product Features
The U.S. Food and Drug Administration
FDA-approved eye drops for glaucoma treatment
Allergan's Lumigan Solution, which contains bimaprost as its main ingredient, is approved by the U.S. Food and Drug Administration.FDA-approved eye drops for glaucoma treatmentis.
Bimaprost, the main ingredient in Lumigan Solution, lowers intraocular pressure and is used to treat glaucoma and ocular hypertension.
In addition, the main ingredient, bimaprost, can cause eyelash damage if the liquid gets on the base of the eyelashes.The effect of eyelash growth and thickening can be seen.
As a side effect of bimaprost has been found to cause eyelash growth and thickening, it has also attracted attention as an eyelash growth agent, and Latisse, which uses the same ingredient (main ingredient) bimaprost, has been released.
In Japan, Allergan Japan has received manufacturing and sales approval from the Ministry of Health, Labor and Welfare as a medical drug, and has marketed it as "Glash Vista," the first drug in Japan to treat eyelash hypotrichosis.
English 
Japanese